Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Part of paid clinical trials in Bloomington, Indiana.
- Sponsor
- Hoosier Cancer Research Network
- Study ID
- NCT01186458
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Lymphoma, Non-Hodgkin
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Fludarabine — DRUGFludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.
- Velcade — DRUGVelcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.
- Rituximab — DRUGRituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
Study Details
The purpose of this study is to determine the effectiveness of fludarabine, Velcade, and rituximab treatment regimen in patients with relapsed or refractory follicular non-Hodgkin lymphoma.
Key Dates
- Start date
- Oct 31, 2010
- Status verified
- Aug 2016
- Primary completion
- Oct 31, 2013
- Completion
- Oct 31, 2013
Study Design
- Enrollment
- 4 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Fludarabine, Velcade and RituximabFludarabine, Velcade and Rituximab
Primary Outcome Measure
Overall Response Rate [ Time Frame: 6 months ]
Locations (11)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cancer Care Center of Southern Indiana | Bloomington | Indiana | 47403 | - |
| Fort Wayne Oncology & Hematology, Inc | Fort Wayne | Indiana | 46815 | - |
| Community Regional Cancer Center | Indianapolis | Indiana | 46256 | - |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | - |
| Arnett Cancer Care | Lafayette | Indiana | 47904 | - |
| Virtua Health Cancer Program | Mount Holly | New Jersey | 08060 | - |
| South Jersey Health Care | Vineland | New Jersey | 08360 | - |
| University of Rochester Medical Center | Rochester | New York | 14642 | - |
| Case Comprehensive Cancer Center - University Hospitals Case Medical Center | Cleveland | Ohio | 44106 | - |
| Seidman Cancer Center | Cleveland | Ohio | 44106 | - |
| Reading Hospital Regional Cancer Center | West Reading | Pennsylvania | 19611 | - |
Find similar trials in Bloomington, IN
By research site
Cancer Care Center of Southern Indiana· Bloomington, INFort Wayne Oncology & Hematology, Inc· Fort Wayne, INCommunity Regional Cancer Center· Indianapolis, INIndiana University Melvin and Bren Simon Cancer Center· Indianapolis, INArnett Cancer Care· Lafayette, INVirtua Health Cancer Program· Mount Holly, NJ
Related Studies
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerPHASE2 · Recruiting · American Society of Clinical Oncology · Birmingham, Alabama
- Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO StudyEnrolling By Invitation · Mayo Clinic · Scottsdale, Arizona
- Long-Term Follow-up StudyEnrolling By Invitation · Caribou Biosciences, Inc. · Birmingham, Alabama
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin LymphomaPHASE1/PHASE2 · Recruiting · Janssen Research & Development, LLC · Duarte, California